DURHAM, N.C., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will webcast the Company's annual investor update on Oct. 22, 2015, from 4:30 p.m. to 6:30 p.m. ET.

To access the live webcast or archived replay, please visit the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669.  For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT: Joseph T. Schepers
         Executive Director, Investor Relations and Corporate Communications
         ir@chimerix.com
         919-287-4125

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.